Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Given Consensus Rating of "Buy" by Brokerages

Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Get Free Report) have earned an average rating of "Buy" from the nine analysts that are presently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. The average 1 year price target among brokers that have covered the stock in the last year is $35.86.

DAWN has been the topic of a number of recent research reports. Needham & Company LLC reissued a "buy" rating and set a $33.00 price target on shares of Day One Biopharmaceuticals in a research note on Monday. Bank of America cut their price target on Day One Biopharmaceuticals from $28.00 to $25.00 and set a "buy" rating on the stock in a research note on Tuesday, January 7th. HC Wainwright reissued a "buy" rating and set a $40.00 price target on shares of Day One Biopharmaceuticals in a research note on Thursday, October 31st. Finally, TD Cowen raised Day One Biopharmaceuticals to a "strong-buy" rating in a research note on Monday, November 4th.

Insider Activity

In other news, insider Samuel C. Blackman sold 30,000 shares of the business's stock in a transaction that occurred on Tuesday, December 10th. The stock was sold at an average price of $13.31, for a total transaction of $399,300.00. Following the completion of the sale, the insider now owns 1,034,015 shares in the company, valued at $13,762,739.65. The trade was a 2.82 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders sold a total of 51,745 shares of company stock worth $748,567 over the last quarter. 8.40% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Day One Biopharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Day One Biopharmaceuticals by 38.4% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,611 shares of the company's stock valued at $51,000 after acquiring an additional 1,002 shares in the last quarter. Quest Partners LLC grew its holdings in Day One Biopharmaceuticals by 9,238.6% during the third quarter. Quest Partners LLC now owns 7,751 shares of the company's stock worth $108,000 after buying an additional 7,668 shares in the last quarter. Point72 DIFC Ltd bought a new stake in Day One Biopharmaceuticals during the second quarter worth $124,000. Hsbc Holdings PLC bought a new stake in Day One Biopharmaceuticals during the second quarter worth $163,000. Finally, Dynamic Technology Lab Private Ltd bought a new stake in Day One Biopharmaceuticals during the third quarter worth $174,000. Institutional investors own 87.95% of the company's stock.

Day One Biopharmaceuticals Trading Up 1.1 %

DAWN stock traded up $0.14 during trading hours on Friday, hitting $12.54. 1,302,478 shares of the stock were exchanged, compared to its average volume of 1,312,420. The firm has a market capitalization of $1.26 billion, a P/E ratio of -12.17 and a beta of -1.46. The company has a 50-day simple moving average of $13.15 and a two-hundred day simple moving average of $13.91. Day One Biopharmaceuticals has a 12 month low of $11.13 and a 12 month high of $18.07.

Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) last issued its quarterly earnings results on Wednesday, October 30th. The company reported $0.38 EPS for the quarter, topping analysts' consensus estimates of ($0.20) by $0.58. The company had revenue of $93.76 million during the quarter, compared to the consensus estimate of $15.05 million. During the same quarter in the previous year, the business posted ($0.54) EPS. On average, equities research analysts predict that Day One Biopharmaceuticals will post -0.85 earnings per share for the current year.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.